SuperworthOutlook Therapeutics OTLK
- Market cap
- $126.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Outlook Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | $1.5M | n/a | −$1.2M | $127.4K | $8.7K−99% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $439.8K | n/a | $29.6K | $149.3K | $17K−96% |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $1.1M | n/a | −$1.2M | −$21.9K | −$8.3K |
| R&D | $4.9M−45% | $4.5M−54% | $13.5M+2379% | $11.2M+1% | $12.5M+153% | $9.7M+113% | $4.4M−67% | $7.1M−36% | n/a | $3.6M−62% | $4.5M+2% | $3.3M−54% |
| SG&A | $7.5M+50% | $5.8M−1% | $5.4M−14% | $8.4M+19% | $10.4M+38% | $11.9M+106% | $8M+47% | $9.7M+16% | n/a | $8.6M−28% | $9.5M+19% | $7.6M−22% |
| −$12.5M−11% | −$10.3M−34% | −$18.9M+177% | −$19.6M+8% | −$22.9M+84% | −$21.6M+109% | −$12.4M−35% | −$15.7M−20% | n/a | −$13.5M−38% | −$14M+13% | −$10.8M−31% | |
| Interest expense | n/a | $188.7K | $3.1M | −$404.6K | $0 | n/a | $18.5K−99% | $49.4K | n/a | n/a | n/a | n/a |
| Pre-tax income | −$13M−9% | n/a | −$114.3M+1618% | $44.4M | $5.7M | n/a | −$46.4M−59% | −$20.2M | n/a | n/a | −$4.5M−90% | −$20.3M+1% |
| $0 | n/a | $2.8K+0% | $0 | $0 | n/a | $2.8K+0% | $0 | n/a | n/a | n/a | n/a | |
| Net income | −$13M−9% | −$11.2M−40% | −$114.3M+1618% | $44.4M | $5.7M | $17.4M | −$46.4M−59% | −$20.2M | −$13.3M | −$23.1M | −$4.5M−90% | −$20.3M+1% |
| −$1.00−17% | −$0.86−46% | −$8.01+1440% | −$0.89−45% | $0.24 | $0.72 | −$1.50−81% | −$0.55−38% | −$0.28 | −$0.38 | −$0.05−97% | −$0.15−73% | |
| 13M+18% | 13M+14% | 14.3M+11% | 25.5M+98% | 23.7M+82% | 24.2M+86% | 30.9M+116% | 37M+45% | 47.1M+99% | 60.2M+148% | 81.8M+165% | 136.7M+270% |
Revenue: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
R&D: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
SG&A: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Operating income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Income tax: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them.
Net income: Q1 FY15 and Q1 FY16: 6 months less the 3 months printed beside them. 19 periods, Q1 FY22 to Q3 FY26: not printed by the filing, worked out from its own lines.
EPS, diluted: 13 periods, Q1 FY15 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY15: share-days: the 6-month average less the second quarter's. 10 periods, Q4 FY15 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY24: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Outlook Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OTLKOutlook Therapeutics | $126.4M | n/m | n/a | n/m | n/m | n/m | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| Peer median | $202.4M | 14.9× | 20.7× | 2.2× | +6% | 10.6% |
More on Outlook Therapeutics
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .